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ABSTRACT: This study investigates how mesenchymal stem cell’s (MSCs) proliferation and migration abilities are influenced by
various platelet products (PP). Donor-matched, clinical-, and control laboratory-standard PPs were generated and assessed based on
their platelet and leukocyte concentrations. Bone marrow derived MSCs were exposed to these PP to quantify their effect on in vitro
MSC proliferation and migration. An adapted colony forming unit fibroblast (CFU-F) assay was carried out on bone marrow aspirate
using clinical-standard PP-loaded electrospun poly(e-caprolactone) (PCL) membrane to mimic future clinical applications to contain
bone defects. Clinical-standard PP had lower platelet (2.5 fold, p< 0.0001) and higher leukocyte (14.1 fold, p< 0.0001) concentrations
compared to laboratory-standard PP. It induced suboptimal MSC proliferation compared to laboratory-standard PP and fetal calf serum
(FCS). All PP induced significantly more MSC migration than FCS up to 24 h. The removal of leukocytes from PP had no effect on MSC
proliferation or migration. The PP-loaded membranes successfully supported MSC colony formation. This study indicates that platelet
concentrations in PP impact MSC proliferation more than the presence of leukocytes, whilst MSC migration in response to PP is not
influenced by platelet or leukocyte numbers. Clinical-standard PP could be applied alongside manufactured membranes in the future
treatment of bone reconstruction. ß 2019 The Authors. Journal of Orthopaedic Research1 Published by Wiley Periodicals, Inc. on
behalf of Orthopaedic Research Society. J Orthop Res
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Fracture nonunion persists as a prevalent complication,
with the incidence in long bones reported to range
between 5 and 10%.1,2 Its etiopathogenesis remains
multifactorial with a recent review identifying over 20
factors to be implicated in this process.3 To address
impaired fracture healing, Giannoudis et al. proposed
the diamond conceptual framework for bone repair
highlighting that, for a successful healing response
both mechanical stability and biological factors must be
present.4 For biological stimulation, while autologous
bone graft remains the gold standard, recently, other
forms have gained popularity including bone marrow
aspirates (BMA) and/or growth factors.5,6 Since their
introduction to the clinical setting, bone morphogenetic
proteins (BMPs) have been extensively used for the
treatment of nonunion fractures.7 There are numerous
publications reporting on the clinical results of BMP-2
and BMP-7.8–10 However, since the withdrawal of
BMP-7 from the market and the license limitation of
BMP-2 to be used for the management of open tibial
fractures, other inductive molecules gained popularity
such as demineralized bone matrix (DBM),11 teripara-
tide,12 and platelet products (PP).13,14
PPs are highly enriched sources of autologous growth
factors and cytokines that act as biological stimulants to
accelerate osteogenesis and bone repair.15,16 PPs are
usually applied as platelet rich plasma (PRP), where the
cells remain intact, or more recently, as platelet lysate
(PL) where only the growth-factor containing plasma is
used.17 Both forms have been found to be highly effective
in the treatment of orthopaedic trauma for decades,18 and
more recently for the treatment of fracture nonunion.19
Several studies into PP loaded membranes are already
proving to be successful at promoting regeneration via
the delivery of growth factors in cartilage and bone
repair.20,21 When working with PP loaded membranes,
maximizing bone marrow derived MSC (BM-MSC) prolif-
eration, and migration is key. By ensuring these func-
tions are enhanced, more viable cells are available to
differentiate, as well as inducing more resident BM-MSC
homing to the site of injury. While some studies found
that the presence of leukocytes in PP are advantageous
due to their antimicrobial properties22 and high concen-
tration of cytokines involved in bone repair such as
VEGF,23,24 there are also concerns related to leukocytes’
effect of inducing excessive inflammatory and necrotic
pathways from the surrounding tissue.25,26 Collectively,
this provides a strong case for their depletion.
This study investigates the in vitro effect of plate-
lets and leukocytes on the proliferation and migration
of MSCs from BMA by studying a range of PP
compositions including a clinical-standard PRP
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(CPRP). A laboratory-standard PRP made using a two-
spin centrifugation protocol to enrich platelets but
deplete leukocytes was also used as control.18,27
To investigate the specific importance of leuko-
cytes, PRP was processed further by syringe-filtra-
tion to remove leukocytes and produce a pure
filtered platelet rich product (fPRP). These prod-
ucts were then lysed to ensure product consistency
over the course of in vitro assays; thereafter
referred to as clinical-standard platelet lysate
(CPL), platelet lysate (PL), and filtered PL (fPL).
These PLs were then evaluated in vitro utilizing
primary BM-MSCs, including autologous BM-MSC-
PP combinations, as well as loading onto a degrad-
able electrospun membrane to achieve sustained
localized delivery in a colony forming units-fibro-
blast (CFU-F) assay. The aim was to assess if high
numbers of leukocytes would impede BM-MSC
proliferation and migration and whether their
depletion from clinical PPs would be desirable for
bone regenerative approaches.
METHODS
This study was carried out in adherence with the Helsinki
Declaration under ethics code 06/Q1206/127 following ap-
proval from the local National Health Service Research &
Development Department, Leeds East Research Ethics Com-
mittee to harvest these samples. Written informed consent
was obtained from each participant.
Sample Collection and Processing of CPRP, PRP, and fPRP
Whole blood was collected from 11 healthy volunteers (8
males and 3 females, 22–58 yrs) in acid-citrate dextrose
solution A (ACD-A). Each sample was divided and used to
prepare CPRP and PRP in a single-donor model. CPRP was
made from whole blood using the BioCUETM device (Zimmer
Biomet) which was centrifuged at 1100 g for 15 min. After
centrifugation, the device was agitated and the CPRP
fraction was extracted using a syringe. PRP was generated
using a two-step centrifugation protocol28 whereby the
patients’ whole blood was incubated at room temperature for
1 h before centrifugation at 400 g for 10 min. The platelet-
containing supernatant was extracted and centrifuged at
2700g for 10 min before resuspending the pellet in 1/5th of
the residual supernatant.
fPRP was generated from PRP that was filtered through a
white blood cell (WBC) syringe filter (Acrodisc) which
entraps leukocytes and allows platelets to pass through for
collection. The division of PRP for the production of fPRP
meant both their final volumes were much smaller than
CPRP limiting the number of assays they could be used in.
Platelet and leukocyte concentrations of CPRP, PRP, fPRP,
and whole blood (1 ml) were determined using an automatic
haematology analyser (Sysmex).
Generating Lysate Products (CPL, PL, and fPL)
To generate the lysed products for in vitro assays, CPRP,
PRP, and fPRP were processed through three freeze-thaw
cycles which involved freezing at   80 ˚C followed by thawing
at 37 ˚C.29 To remove contaminating cell debris, CPL, PL,
and fPL were centrifuged at 2700g for 10 min and the
supernatants were extracted for cell stimulation.
Sample Collection and Processing of BM-MSCs
Patients undergoing elective orthopaedic surgery with no
underlying disease were recruited (n¼ 11, 6 males and 5
females, 17–69 yrs). 4 ml of BMA was collected from each
donor’s anterior iliac crest and was treated with ammonium
chloride to lyse red blood cells. The remaining nucleated cells
were plated into flasks at the cell seeding density of 5 105
cells/cm2. BM-derived adherent cells were cultured in MSC
expansion media (Miltenyi Biotec) for approximately 2 weeks
until confluent.
Characterising BM-MSCs
Cultured BM derived cells (passage two) were tested for
the surface expression levels of MSC markers as defined by
the International Society for Cell Therapy (ISCT).30 Follow-
ing trypsinisation (Sigma Aldrich), cell cultures were
stained with antibodies against positive markers of MSCs
(CD90, CD73, and CD105) and negative hematopoietic-
lineage markers (CD34, CD14, HLA-DR, CD19, CD45). All
antibodies were used according to the manufacturer’s
recommendation (Miltenyi Biotec). Isotype controls (BD,
Bio-Rad) were used to gate for positive expression. The
data were acquired on an Attune flow cytometer (Thermo-
Fisher Scientific).
Trilineage Differentiation Potential of BM-MSCs
BM derived cells were cultured up to passage four before
being trypsinized and tested for multipotentiality as previ-
ously described.31 Cells were seeded with AdipoDiff Media
(Miltenyi Biotec) or OsteoDiff Media (Miltenyi Biotec) for
adipogenesis or osteogenesis, respectively, with bi-weekly
media changes. After 3 weeks, cell cultures were stained
with oil red solution (adipogenesis)32 or Alizarin Red (osteo-
genesis). For chondrogenesis, cells were added to Eppendorf
tubes to create a pellet, resuspended in ChondroDIFF Media
(Miltenyi Biotec) and cultured for 21 days after which the
pellets were stained with toluidine blue (Sigma).
Proliferation Assay
The XTT assay was used to quantify BM-MSC proliferation
in the presence of different PL products. Activity of mito-
chondrial dehydrogenase, and therefore cell number per well,
is directly correlated to the amount of orange formazan
formed, as monitored by the optical density (OD) at 450 nm.
BM-MSCs were seeded in triplicate in a 96-well plate at a
density of 500 cells/well with MSC expansion media and
incubated for 24 h. The media was then replaced with basal
Dulbecco’s Modified Eagle’s Media (DMEM; Sigma-Aldrich)
supplemented with 10% (v/v) of CPL, PL, fPL, or fetal calf
serum (FCS) and incubated for 5 days with a half media
change on day 3. Following exposure to the treatment media,
cell proliferation was assessed on day 5 using an XTT cell
proliferation kit (Roche) according to the manufacturer’s
instructions.
Migration Assay
The bottom wells contained basal DMEM (1% (v/v) Penicillin/
Streptomycin and 2 I.U/ml sodium heparin solution) supple-
mented with 10% (v/v) of CPL, PL, fPL, or FCS. 10% was the
selected concentration due to its frequent use in the
literature.33–35 Migration was analyzed over 24 h using an
IncuCyte1 (Essen) to collect phase-contrast images of the
transwells as cells migrated along the chemotactic gradient.
Images were captured every 30 min and a processing mask
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was created for each BM-MSC culture to account for donor
variation.
CFU-F Assay With CPL-Loaded Membrane
An adaptation of the CFU-F assay was used to quantify
how a CPL-loaded membrane affected the proliferation and
migration capacity of uncultured BM-MSCs and to further
validate the results of the assays using cultured BM-MSCs.
First, fresh BMA from three donors underwent red blood
cell lysis after which a total of 5 105 cells were plated in
15 ml expansion media to adhere over 24 h. After initial
attachment and a PBS wash the media was replaced with
either 15 ml expansion media containing 2 I.U/ml sodium
heparin solution (control) or 15 ml DMEM media (no
serum) containing 2 I.U/ml sodium heparin solution (test).
1 cm2 square sections, 400 mm thick, of UV-sterilized PCL
that were made in-house36 were soaked in CPL for 15 min
until saturated before being placed in the centre of the test
dishes. The dishes were incubated for a further 19 days
with half-media changes once a week. After 21 days, the
dishes were washed in PBS, fixed in 10% (v/v) formalin
(Sigma) and stained in 1% (w/v) methylene blue (Sigma).
All colonies were imaged using a plate scanner (Epson) at
1200 dpi. Colony area, integrated density and number per
dish was quantified using ImageJ whereby scanned images
were converted to 8-bit grayscale and a threshold mask
was applied before particles were automatically analyzed
and measured.
RESULTS
Characterising Cellular Content of PP
CPRP was generated using a BioCUETM device
whilst PRP was made following a previously opti-
mised protocol18 and their cell populations were
quantified using a haematology analyzer. While
both PP significantly enriched platelets compared
to their whole blood counterparts, PRP also had
Figure 1. Characterising platelet rich plasma products. Using a haematology analyser, the change in platelets (A), leukocytes (B),
and final volume (C) from whole blood to CPRP (n¼ 11) and PRP (n¼ 11) were quantified. The increase or decrease of each cell type
indicates the change from whole blood (red) to the paired platelet product (black). A paired t-test was used to compare change in cell
type before and after processing (p<0.01, p<0.001, and p<0.0001) while a Mann-Whitney test was used to compare CPRP
and PRP (#¼p< 0.001, # #¼p<0.0001). Statistics could not be conducted on CPRP’s volume analysis (C) due to matching differences
between each sample. The photographs show the CPRP fraction product (D) and the PRP product (E).
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significantly higher numbers of platelets (15.9105
PLT/mlL) (Fig. 1A) in comparison to CPRP
(6.3105 PLT/ml) as well as significantly lower
leukocyte numbers (1.8103 LEUK/ml) compared to
CPRP (20.6103 LEUK/ml) (Fig. 1B). Despite the
significant difference in final volumes (p¼ 0.0078)
(Fig. 1C), both products had comparable average
fold decrease in volumes (10.00.0 and 7.90.5
CPRP and PRP, respectively). All CPRP replicates
underwent identical reductions in volume causing
their data points to overlap. The difference in the
PP’s cell populations is also visible in their appear-
ance as CPRP is opaque with additional red blood
cell contamination (Fig. 1D) while PRP had fewer
contaminating red blood cells and was more trans-
lucent (Fig. 1E).
As previous studies have found that platelets and
leukocytes are not stable at room temperature for
the 5 days necessary for the proliferation and
migration assays,37 the PP were lysed after produc-
tion to ensure consistency of samples. Lysis of the
products changed their nomenclature from CPRP
and PRP to clinical platelet lysate (CPL) and
platelet lysate (PL).
Characterizing BM-MSCs
BMAs underwent red blood cell lysis, after which the
remaining nucleated cells were plated into flasks,
three randomly selected cultures were tested for MSC
characterization according to the ISCT’s definition.38
Cell surface marker expression was analyzed using
flow cytometry which found cells were negative for
CD14, CD19, CD34, CD45, HLA-DR, and positive for
CD73, CD90, and CD105 (Fig. 2A) consistent with the
criteria for identifying MSCs. Their tri-lineage differ-
entiation capacity was confirmed following 3-week
culture in adipogenic, osteogenic, and chondrogenic
stimulation medias. A representative culture is shown
in Figure 2 which was stained with oil red o solution
to visualize lipid droplets (Fig. 2B), alizarin red
staining to visualize calcium depositions (Fig. 2C), and
finally toluidine blue staining of the aggregated cell
pellet indicative of glycosaminoglycan production.
Nine of these cultures were used for subsequent PL
proliferation and migration tests, each PL product was
tested on at least three MSC cultures and the results
were averaged.
Platelet Product Composition’s Impact on BM-MSC
Proliferation
Cultured cells were exposed to 10% PL, CPL, and
control FCS containing media for 5 days, after which
the cells were treated with XTT reagent causing a
color change. BM-MSC proliferation was expressed as
OD normalized to FCS. BM-MSCs treated with PL
were found to proliferate significantly more than cells
treated with CPL (p¼ 0.0001) and equal to cells
treated with FCS (Fig. 3A). The same response was
also seen from BM-MSCs tested with autologous PL
and CPL (Fig. 3B). To investigate whether CPL’s
suboptimal support of BM-MSC proliferation was due
to the high number of leukocytes, they were filtered
out using a leukocyte syringe filter. The filtered PL’s
(fPL) platelet numbers were not significantly affected
Figure 2. Platelet product composition’s impact on BM-MSC proliferation. XTT assay quantifying BM-MSC proliferation following
four day exposure to media containing 10% platelet products or FCS as control. Proliferation was represented as OD normalized to
FCS. (A) Cultured BM-MSCs were exposed to 10% PL, CPL, and FCS. (B) Cultured BM-MSCs were exposed to autologous 10% PL and
CPL as well as 10% FCS. (C) The change in platelets and leukocytes from whole blood to PRP and fPRP (compared using a paired t-
test). (D) Cultured BM-MSCs were exposed to 10% PL, fPL and FCS from three PL donors. One-way ANOVA test was used to test
significance between the platelet products effects on proliferation (3A, B, and D).(P<0.05, P< 0.01, P<0.001, and P< 0.0001).
Except for 3B, all experiments were performed on a minimum of three different PP donors and three BM-MSC cultures. Error bars
indicate variation between PP except for 3B where error bars indicate technical variation between replicates.
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by the filtration process while leukocytes were shown
to be significantly depleted in fPL (Fig. 3C). Removal
of the leukocytes was found to not significantly
improve proliferation as it was shown that both PL
and fPL induced the same BM-MSC proliferation as
FCS (Fig. 3D).
Altogether, this data indicated that the leukocytes
were not inhibitory for BM-MSC proliferation and
suggested that differing performances of PL and CPL
observed were likely due to the different numbers of
platelets present.
Platelet Product Composition’s Impact on BM-MSC
Migration
To compare the chemotactic potential of the different
PPs, the IncuCyte1 transwell assay was used. Serum
starved BM-MSCs were seeded on top of the trans-
wells and exposed to different PPs below. Over the
course of 24 h, the top and bottom of the transwells
were imaged continuously to track their migration.
Representative images of the top of the transwells are
shown in Figure 4A where non-migrated cells are
shown in focus (purple arrow), cells that have mi-
grated through and identified by the software are
highlighted in green for processing (blue arrow) and
the pores are identified with black arrows. The
migratory effects of PL and CPL were demonstrated as
a time-course assay using one representative culture
(Fig. 4B) which showed that, both PL and CPL appear
to induce far more migration than 10% FCS. To enable
statistical analysis, three independent PL prepara-
tions were each tested on three BM-MSC cultures and
found that both PL and CPL induced significantly
more migration than FCS at 12 h (p¼0.0068 and
p¼ 0.0434, respectively) and at 24 h (p¼ 0.0006 and
p¼ 0.0008) (Fig. 4C). Considering the higher levels of
leukocytes in CPL, these findings suggest that the
presence of leukocyte-derived proteins is not a detri-
ment to BM-MSC migration and potentially contribute
toward improved migration.
To further investigate the effect of leukocyte-de-
rived proteins on BM-MSC migration, PL and fPL’s
chemotactic effects were investigated. A representative
culture is shown in Figure 4D which showed that,
while the complete removal of leukocytes did appear to
reduce BM-MSC’s migratory response this reduction
was not statistically significant. In addition, PL and
fPL both induced far more migration than 10% FCS.
BM-MSCs were found to be significantly more migra-
tory toward PL and fPL than 10% FCS at 12 h
Figure 3. Platelet product composition’s impact on BM-MSC migration. The IncuCyte1 transwell assay quantifies BM-MSCs moving
toward a chemotactic gradient. (A) Representative images of wells of 0.5% FCS (top), 10% FCS (middle), and 10% PL (bottom). Arrows
indicate pores (black), static cells on the top of the transwell (purple) and cells that have migrated (blue). The processing mask that
quantifies the migrated cells is shown in green. (B) Representative time-course response of the cells from one BM-MSC culture that
have migrated through the transwell towards 10% PL, 10% CPL 10% FCS, and 0.5% FCS. Data are shown as the area of the bottom of
the well occupied by cells. (C) Average object area of the underside of the transwell occupied by BM-MSCs and treated with 10% PL,
10% CPL, and 10% FCS was normalized to 10% FCS. (D) Representative time-course response of the cells from one culture that have
migrated through the transwell towards 10% PL, 10% fPL, 10% FCS, and 0.5% FCS. (E) Average object area of the underside of the
transwell occupied by BM-MSCs and treated with 10% PL, 10% fPL, and 10% FCS was normalized to 10% FCS. A one-way ANOVA
was carried out using the Kruskal-Wallis test for normality (p<0.05, p< 0.01, p<0.001, and p< 0.0001). Error bars indicate
variation between PL donors. Experiments in C and E were performed on a minimum of three different BM-MSC cultures.
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(p¼0.0015 and 0.0198, respectively) and PL was also
found to outperform 10% FCS at 24 h (p¼0.0024)
(Fig. 4E). These findings suggest that while platelet
and leukocyte numbers contribute toward BM-MSC
migration, it is likely that most of the cytokines that
induce migration are present in the plasma component
of PP—and so any additional platelet or leukocytes
make no significant difference.
Loaded Membrane Supports Colony Formation From
Native MSCs Present in BMA
To more closely mimic clinical applications involving a
PP-loaded biomaterial membrane as a MSC homing
and containment device, experiments were performed
using clinically approved PP. The aim of these experi-
ments was to study if CPL released from a membrane
could support colony formation from rare BM-MSCs
without their culture-amplification. In standard CFU-
F assays, single rare BM-MSCs give rise to individual
colonies. The fresh BM-MSCs used for this assay were
grown in either standard MSC expansion media or
basal serum-free media with the addition of a CPL-
loaded membrane (Fig. 5A). Colony formation was
observed in all test dishes, with similar morphology to
control dishes containing MSC expansion media
(Fig. 5B). Furthermore, although there were trends for
higher colony numbers in MSC expansion media, and
higher colony areas and densities in CPL-loaded
membrane dishes, the differences were not found to be
statistically significant (Fig. 5C). This indicated that
CPL-loaded membranes were able to release growth
factors that induced colony formation and supported
rare BM-MSC proliferation.
DISCUSSION
While the clinical effectiveness of PP is generally
accepted, due to the lack of quality control, the
variation in manufacturing, processing, delivery, and
its different applications (e.g., rotator cuff repair and
osteoarthritis39,40), the “optimal” composition is still
hotly debated depending on its specific clinical applica-
tion.
The main issue with lack of standardization is
exemplified by one study which found that PRP had no
significant effect on bone healing,41 however, a closer
look at the platelet numbers used in the study found
that some of the PRP tested had over 16-fold more
platelets than other PRP. Despite the vast differences
in platelet numbers and omitted leukocyte numbers,
these products were all classified under the same
umbrella term “PRP.” This is commonplace across the
literature, whereby, the absence of standardized no-
menclature, quality control, as well as thorough analy-
sis of cellular contents, makes it difficult to draw clear
Figure 4. CPL-loaded membrane supports cell proliferation in CFU-F assay. (A) Representative CFU-F dishes of BM-MSCs grown in
either standard expansion media (top dish) or serum-free DMEM with the additional CPL-loaded membrane as a source of released
growth factors and cytokines (bottom dish). (B) Representative individual colonies of cells grown in expansion media (top) or CPL-
loaded membrane and DMEM (bottom). Three BMA donors were tested on a single CPL product. Images were collected using a photo
scanner at 1200 dpi. (C) Comparison of average colony area, density, and total number between cells treated with a CPL-loaded scaffold
and expansion media (EM). An unpaired t-test found no significant difference between CPL of EM.
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conclusions. According to Delong et al.’s classification
system42 platelet number, activation method, and
white blood cell number (PAW), CPRP is classified as
P2-A (which identifies the increase of platelets as
“moderate” and the leukocytes as “enriched above
baseline”) while PRP is classified as P3-B (which
identifies the platelet concentration as “highly
enriched” above baseline and leukocytes depleted
below baseline).
As well as variation in platelet concentrations, the
lack of regulation also instils concern in the scientific
community over the use of highly concentrated leuko-
cytes, their associated pro-inflammatory cytokines
(specifically TNF-a and IL-1b), and the risk that they
could counteract the platelet’s beneficial effects and
impede bone regeneration.26 TNF-a and IL-1b are
known to induce inflammation causing a biphasic
physiological response; whilst inflammation is neces-
sary for healing,43 in excess it is thought to activate
the NFkB pathway26 inhibiting osteogenesis and pro-
moting osteoclastogenesis.44 However, more recently,
these proinflammatory cytokines have been linked to
increased osteogenesis,45 BM-MSC migration,46 and
proliferation47 indicative of the lack of consensus in
the field.
This study addressed these concerns by better
defining platelets and leukocyte’s effects in the two
key physiological processes of bone regeneration: BM-
MSC proliferation and BM-MSC migration. With
regards to proliferation, when compared to PL and
FCS, CPL induced significantly less BM-MSC prolifer-
ation than PL. This was also observed using donor-
matched BM-MSCs and PP proving that the response
from the cells was not due to the allogeneic nature of
the PL. The cause of CPL’s suboptimal ability to
support BM-MSC proliferation compared to PL is
either due to its lower number of platelets or higher
number of leukocytes—both of which have been
reported to reduce proliferation in the litera-
ture.26,42,48,49 To identify which cell type is the key
Figure 5. Characterizing platelet rich plasma products.
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player, leukocytes were filtered from PL while platelet
numbers were kept the same to produce fPL. Direct
comparison of PL and fPL showed that removing
leukocytes did not improve proliferation. This suggests
that in our experimental conditions, the cytokines
released from leukocytes neither enhanced nor inhib-
ited BM-MSC proliferation and that platelets are most
likely responsible for releasing the predominant
growth factors involved in supporting BM-MSC prolif-
eration.
With regards to BM-MSC migration, all three plate-
let products (PL, CPL, and fPL) induced significantly
more migration than FCS, likely due to the greater
concentrations of cytokines such as VEGF and SDF-
1.50,51 Again, it was seen that removing leukocytes from
PL did not further enhance BM-MSC migration, but
even seemed to reduce it. While there is no precedent
for the use of platelet products in BM-MSC migration
studies, the current data supports previous literature of
platelet products outperforming FCS.26,34 The methods
used are also unique in that, not only is the total
migration shown, but also the increased rate of cell
migration toward the platelet products.
Based on these findings it could be proposed that
generating high quality platelet products should simply
involve increasing platelet numbers as much as possi-
ble without regard for leukocytes—this could be easily
achieved by decreasing the final volume to yield a more
concentrated platelet product. However, the excessive
enrichment of platelets faces the risk of paradoxically
inhibiting cell proliferation, viability, and migration.42
A therapeutically effective range of platelet concentra-
tion is likely to be the case rather than a specific pure
concentration. Our results indicate that platelet con-
centrations in the range of 6.3–15.9105 PLTs/ml (with
and without leukocytes) were effective in supporting
BM-MSC proliferation and migration without adverse
effects on their attachment or morphology.
While several studies have already shown that PP
increases the bone regeneration rate and prevention of
non-union fractures in animal models52,53 and human
subjects,14 as well as this work that aims to optimize
PP’s impact on BM-MSCs, it is also important to
consider how PP should be delivered to the site of
injury. To address this, a membrane was loaded with
CPL and its discharge was found to support BM-MSC
colony formation and BM-MSC proliferation. Due to
the manufacturing process of PL and fPL (specifically
the division of samples), low volumes prevented their
loading onto a membrane for CFU-F analysis. In
summary, this study supports the notion that the
specific clinical application and desired outcome
should be considered for defining best formulations of
platelet products for bone regeneration. If cell prolifer-
ation is thought to be limiting regeneration, for
example in elderly patients that have low numbers of
autologous BM-MSCs,54 then CPL will be sub-optimal
and PP with higher concentrations of platelets should
be used. If however, the surgeon’s priority is to induce
BM-MSC migration to the site of injury, for example
to attract BM-MSCs toward an unpopulated bone
scaffold, then the current clinical standard CPL may
be sufficient. As well, CPL was found to support colony
formation when delivered using a membrane, with a
trend of increased colony size and density than MSC
expansion media; providing encouraging insight to-
ward future delivery alternatives and streamlined
surgeries.
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